UPDATE: Forget GVBP’s main “partner” denying not just a partnership but ever having talked with GVBP (read below), we now know that GVBP’s 3 miraculous cancer and stem calls patents are the EXACT same as NextGen Biosciences (NXGB) which went under late last year, not to mention having the same address and executives involved!
You know I’ve been reporting a lot on this GVBP pump & dump:
-GVBP’s address is the same as a known penny stock spammer
-after just 4 days, GVBP was forced to retract a PR about one of their collaboration agreements
-GVBP has been using recycled press releases
-2 videos some other traders made about GVBP
-GVBP’s partners have the same address?!?!?!
-how an insider with 100 million shares has started selling 3 million of them…at 27 cents/share
…and I know I’m getting through to a few people, but even I was surprised to come home and find these emails from the CEO of Bridge Bio, Søren Stenderup, the company that Genova announced had ended “their relationship” after just 4 days in a late night press release Friday night (the time slot public companies use to announce news they don’t want anyone to notice):
I’ll let Soren speak for himself as he assures me his company NEVER had a dialogue with Genova, Genova made the whole thing up, so it’s impossible to end a relationship that never existed in the first place (long story short: Genova is ****ed, you can’t go around making up things and distributing them everywhere via press releases, that’s not just an SEC violation, that’s illegal)
Tim – I am the CEO of BBR. What you have seen is not the full story.
Genova has issued two press releases without the knowledge of BBR management – and there are no contracts and we have never been in dialogue with them In fact I did not know the company existed before early morning Thursday the 17th.
I have informed Genova that a clarification is neded because:
“You simply cannot state “that it has ceased the relationship with Bridge BioResearch PLC” because there never was a relationship”
…and just a few hours later:
Further to the below – for clarification:
Genova has issued two press releases without the knowledge of BBR management
For further you can call me on ******** – or email. I will share any information I have on these people – just look at the CEO´s CV. He seems to be recycled.
Aaron Whiteman – Chief Executive Officer Ridgeback Mining
Aaron Whiteman holds a Bachelors of Law Degree from Oxford University and an MBA from the London School of Economics. Most recently, he served as a Vice President of Reliance Entertainment, India’s largest entertainment company, responsible for operations, business development and expansion into the European, Middle Eastern, and African regions. Prior to that, from May 2002 through May 2007, Mr Whiteman was a Vice President of Business Development at Game Federation, where he was responsible for promotion of the company’s products to strategic telecom partners globally. During his tenure, he successfully secured licensing agreements and commercial alliances with telecom giants such as Vodafone, T-Mobile, France Telecom and AT&T along with entertainment companies like Disney, Electronic Arts, Vivendi. He has also held various executive, board, and advisory positions in the telecommunication industry.
Aaron Whiteman – Chief Executive Officer Genova
Mr. Aaron Whiteman holds a Bachelors of Law Degree from Oxford University and an MBA from the London School of Economics. Most recently, he served as a vice president of Reliance Biotech, an Indian medical research company, responsible for business development and expansion into the European, Middle Eastern, and African regions. Prior to that, from May 2002 through May 2007, Aaron Whiteman was a vice president of Viranative AB, where he was responsible for promotion of the company’s products to strategic partners in the Sub-Saharan region. During his tenure, he successfully secured licensing agreements and commercial alliances with pharmaceutical giants Pharmacia (Upjohn), Astra Zeneca, and Glaxo Smith Kline. He has also held various executive, board, and advisory positions in the telecommunications industry.
And check their web – “investors” – “Industry news”
Regards
Søren Stenderup
CEO
Bridge BioResearch PLC
And then just to make sure I was getting the story straight, one last email:
Hi Tim
From my point of view this is pretty simple.
Genova has used the name of Bridge BioResearch PLC and one of our employees without our knowledge and consent.
An unconditional retraction regarding this has now been issued – and a short statement appears on the Genova Homepage. I have however yesterday (when the above release come to my attention) pointed out to Aaron Whiteman of Genova that submission of a clarification is needed. Genova cannot claim “that it has ceased the relationship with Bridge BioResearch PLC” – simply because there never was a relationship” I am sure that Mr. Whiteman understands this.
Just for the record – the issued press release was never mailed to me for approval. I had dialogue through a Genova advisor/consultant late Friday – regarding a press release proposal.
This proposal I changed to match our requirements – and I believed that Genova would comply. Sadly this was not the case and we are therefore demanding the above clarification.
Below is the PR Soren wanted Genova to release and “believed that Genova would comply”…he goes further saying, “Sadly this was not the case and we are therefore demanding the above clarification.”:
NEW YORK, NY, Sept. 18, 2009 – (OTCBB: GVBP.OB) – GENova Biotherapeutics Inc. (”GENova”) today announced that at no time has GENova Therapeutics Inc. ever had any dealings with Bridge BioResearch PLC or entered into any formal relationship or discussions with Bridge BioResearch PLC. The PR Release of September 14th 2009 stating a collaboration agreement with Bridge BioResearch PLC was published without any knowledge to the Board of Directors of Bridge BioResearch PLC.
Further the PR Release of September 8th 2009 regarding appointment of Bridge BioResearch CSO, Mr. Anders Bøgh Jensen as GENova advisory board member, was published without any knowledge to the Board of Directors of Bridge BioResearch PLC or prior contact to Mr Anders Bøgh Jensen.
The Directors of Bridge BioResearch PLC and Mr. Anders Bøgh Jensen has made it clear that there is no intention of entering any formal relationship with GENova.
The directors of GENova Biotherapeutics Inc. takes full responsibility for the publication of the above press releases which hereby are retracted unconditionally.
In case you had any questions regarding the definitions of “dialogue” and “collaboration”, Soren also included the following:
A dialogue (sometimes spelled dialog) is a conversation between two or more people. It is also a literary form in which two or more parties engage in a discussion.
Collaboration is a recursive process where two or more people or organizations work together in an intersection of common goals — for example, an intellectual endeavor[1] [2] that is creative in nature[3]—by sharing knowledge, learning and building consensus. Most collaboration requires leadership, although the form of leadership can be social leadership within a decentralized and egalitarian group.[4] In particular, teams that work collaboratively can obtain greater resources, recognition and reward when facing competition for finite resources.[5]Collaboration is also present in opposing goals exhibiting the notion of adversarial collaboration, though this is not a common case for using the term.
Disclaimer: I am currently short 30,000 shares of Genova (GVBP) because after all my research, my for entertainment purposes only opinion, even though I am in no way a financial advisor, nor is this is not a recommendation to buy or sell any securities, you should always consult a financial advisor, is that GVBP is 100% worthless and my goal is to buy to cover my shares under 5 cents/share.
Tags: Manipulation
